Murali Ramachandran 4
4 · Kairos Pharma, LTD. · Filed Feb 24, 2025
Insider Transaction Report
Form 4
Murali Ramachandran
VP of Research and Development
Transactions
- Award
COMMON STOCK
2025-01-01+14,000→ 147,057 total
Footnotes (2)
- [F1]Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof.
- [F2]Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting.